HomeCompareCGASY vs ABBV

CGASY vs ABBV: Dividend Comparison 2026

CGASY yields 4.35% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $74.4K in total portfolio value
10 years
CGASY
CGASY
● Live price
4.35%
Share price
$26.91
Annual div
$1.17
5Y div CAGR
3.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.9K
Annual income
$813.55
Full CGASY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CGASY vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCGASYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CGASY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CGASY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CGASY
Annual income on $10K today (after 15% tax)
$369.74/yr
After 10yr DRIP, annual income (after tax)
$691.52/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,364.49/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CGASY + ABBV for your $10,000?

CGASY: 50%ABBV: 50%
100% ABBV50/50100% CGASY
Portfolio after 10yr
$65.1K
Annual income
$12,792.66/yr
Blended yield
19.64%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CGASY
No analyst data
Altman Z
1.5
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CGASY buys
0
ABBV buys
0
No recent congressional trades found for CGASY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCGASYABBV
Forward yield4.35%3.06%
Annual dividend / share$1.17$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR3.1%40.6%
Portfolio after 10y$27.9K$102.3K
Annual income after 10y$813.55$24,771.77
Total dividends collected$6.2K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CGASY vs ABBV ($10,000, DRIP)

YearCGASY PortfolioCGASY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,148$448.47$11,550$430.00$402.00ABBV
2$12,411$481.75$13,472$627.96$1.1KABBV
3$13,796$516.74$15,906$926.08$2.1KABBV
4$15,315$553.49$19,071$1,382.55$3.8KABBV
5$16,979$592.05$23,302$2,095.81$6.3KABBV
6$18,800$632.45$29,150$3,237.93$10.3KABBV
7$20,791$674.76$37,536$5,121.41$16.7KABBV
8$22,966$719.01$50,079$8,338.38$27.1KABBV
9$25,338$765.26$69,753$14,065.80$44.4KABBV
10$27,926$813.55$102,337$24,771.77$74.4KABBV

CGASY vs ABBV: Complete Analysis 2026

CGASYStock

China Resources Gas Group Limited, an investment holding company, engages in the sale of liquefied gas and connection of gas pipelines. The company operates through Sale and Distribution of Gas Fuel and Related Products, Gas Connection, Sale of Gas Appliances, Design and Construction Services, and Gas Stations segments. The Sale and Distribution of Gas Fuel and Related Products segment sells natural gas and liquefied petroleum gas for residential, commercial, and industrial use. The Gas Connection segment engages in the construction of gas pipeline networks under gas connection contracts. The Sale of Gas Appliances segment sells gas appliances and related products. The Design and Construction Services segment provides design, construction, consultancy, and management services for gas connection projects. The Gas Stations segment sells gas fuel in natural gas filling stations. As of December 31, 2021, it operated 266 city gas projects in 22 provinces in the People's Republic of China. The company is headquartered in Wan Chai, Hong Kong. China Resources Gas Group Limited is a subsidiary of China Resources (Holdings) Company Limited.

Full CGASY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CGASY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CGASY vs SCHDCGASY vs JEPICGASY vs OCGASY vs KOCGASY vs MAINCGASY vs JNJCGASY vs MRKCGASY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.